aQALYs: Quality Adjusted Life YearsbICUR: Incremental Cost-Utility RatiocICER: Incremental Cost-Effectiveness RatioCost-effectiveness: base case results.
Introduction This study aims to assess the cost effectiveness of romosozumab versus teriparatide, both sequenced to denosumab, for the treatment of severe postmenopausal osteoporosis at very high risk
IntroductionThis study aims to assess the cost effectiveness of romosozumab versus teriparatide, both sequenced to denosumab, for the treatment of severe postmenopausal osteoporosis at very high risk